Egetis Therapeutics AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 12.2 million compared to SEK 5.1 million a year ago. Revenue was SEK 12.2 million compared to SEK 5.2 million a year ago. Net loss was SEK 86.2 million compared to SEK 53.9 million a year ago. Basic loss per share from continuing operations was SEK 0.3 compared to SEK 0.3 a year ago. Diluted loss per share from continuing operations was SEK 0.3 compared to SEK 0.3 a year ago.
For the nine months, sales was SEK 25 million compared to SEK 16.9 million a year ago. Revenue was SEK 25 million compared to SEK 17 million a year ago. Net loss was SEK 240.7 million compared to SEK 115.9 million a year ago. Basic loss per share from continuing operations was SEK 1 compared to SEK 0.6 a year ago. Diluted loss per share from continuing operations was SEK 1 compared to SEK 0.6 a year ago.